ANGLE's Parsortix device plays critical role in ground-breaking research on cancer spread

ANGLE PLC’s (LON:AGL) chief executive Andrew Newland talks Proactive London through some ground-breaking research their liquid biopsy system has been used in to assess the role of the body’s own immune suppressor cells in promoting the cancer spread.

Its Parsortix device proved efficient at harvesting circulating tumour cell clusters and was superior to the competing method of collection on two levels: the size of the cluster and Parsortix’s ability to successfully extract these large clusters 100% of the time.

It emerged that large circulating tumour cell clusters were fifty-times more likely to generate metastasis than single circulating tumour cells.

Quick facts: ANGLE PLC

Price: £0.73

Market: AIM
Market Cap: £126.11 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...



Full interview: Enertopia completes spring and summer testing program,...

Enertopia Corp (CSE: TOP) President and CEO Robert McAllister sat down with Steve Darling from Proactive Vancouver to bring news the company has wrapped up their spring and summer testing program for pre-strip reagent testing to control impurity levels in the Upper Oxide and Reduced drilled...

20 hours, 11 minutes ago

2 min read